Lundbeck in licensing deal with Confo Therapeutics

Danish CNS specialist Lundbeck is to pay an initial five million euros ($5.9 million) to use the technology of Belgian drug discovery company Confo Therapeutics to discover small molecule compounds acting upon two G-protein coupled receptors.

There will also be further milestone payments, as well as tiered royalties on the annual net sales of any products resulting from the collaboration, which gives Lundbeck an option to an exclusive license to develop, manufacture and commercialize such compounds.

Working on GPCRs that Lundbeck has not been able to address previously will allow the company to initiate new projects in its preclinical portfolio for schizophrenia, depression, Alzheimer’s and Parkinson’s disease.